Skip to content

Released Feb 28, 2017

10-K filed Feb 28, 2017, 59 days after period end · 0001232524-17-000024

Q4 2016 · 10-K
Revenue$396.62M+16.4% vs Q4 2015+6.0% vs Q3 2016
Net Income$116.69M+41.0% vs Q4 2015+29.9% vs Q3 2016
EPS Diluted$1.91+44.7% vs Q4 2015+31.7% vs Q3 2016
Gross Profit$358,958,000+14.0%
Operating Incomederived$165,504,000+55.2%
Operating Cash Flowderived$180,695,000+50.9%
Free Cash Flowderived$179,418,000+54.2%
Margins · derived
Gross margin90.5%−1.9 pt vs Q4 2015
Operating margin41.7%+10.4 pt vs Q4 2015
Net margin29.4%+5.1 pt vs Q4 2015

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2016Q4 2015Q4 2014Q4 2013
Revenue$396.62M$340.88M$328.14M$235.77M
Net Income$116.69M$82.76M$81.61M$55.29M
EPS Diluted$1.91$1.32$1.30$0.90

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR